National Comprehensive Cancer Network
3025 Chemical Road, Suite 100
Plymouth Meeting
Pennsylvania
19462
United States
Tel: 215-690-0300
Website: https://www.nccn.org/
Email: jobs@nccn.org
About National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of 28 leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, efficient, and accessible cancer care so patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system.
By defining and advancing high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers around the world. World-renowned experts from NCCN Member Institutions diagnose and treat patients with a broad spectrum of cancers and are recognized for dealing with complex, aggressive, or rare cancers. NCCN Member Institutions pioneered the concept of the multidisciplinary team approach to patient care and conduct innovative research that contributes significantly to understanding, diagnosing, and treating cancer. NCCN programs offer access to expert physicians, superior treatment, and quality and safety initiatives that continuously improve the effectiveness and efficiency of cancer care globally.
NCCN 20th Anniversary Video - Improving Cancer Care Together
January 31, 2015 marked the 20th anniversary of the National Comprehensive Cancer Network; originally announced as an alliance of 13 leading cancer centers in 1995, NCCN has grown to a network of 26 academic cancer centers devoted to patient care, research, and education.
Featuring past and present leadership, this video describes the groundbreaking accomplishments of NCCN over the past two decades that have improved the quality, effectiveness, and efficiency of cancer care so that patients can live better lives.
145 articles about National Comprehensive Cancer Network
-
New National Comprehensive Cancer Network Guidelines Include Evidence Blocks To Illustrate Value In Breast, Colon, Kidney, And Rectal Cancers
2/12/2016
-
National Comprehensive Cancer Network Awarded $2 Million In Research Funding From Infinity Pharmaceuticals Inc. To Study Duvelisib In Hematologic Malignancies
2/9/2016
-
National Comprehensive Cancer Network Awards Research Grants To Five Investigators To Study Effectiveness Of Enzalutamide In Various Cancers
1/14/2016
-
Peregrine And National Comprehensive Cancer Network (NCCN) Form Clinical Collaboration To Evaluate Novel Cancer Treatment Combinations With Bavituximab
1/6/2016
-
Myriad Genetics, Inc. Release: National Comprehensive Cancer Network Updates Guidelines For Hereditary Colon Cancer Testing
3/4/2014
-
Researchers Receive Grants From National Comprehensive Cancer Network Oncology Research Program Funded Through AVEO Oncology (Formerly known as AVEO Pharmaceuticals, Inc.)/Astellas Pharma Inc. Collaboration
10/15/2012
-
National Comprehensive Cancer Network Appoints Dr. Robert Carlson as CEO
9/24/2012
-
Researchers Receive Grants From National Comprehensive Cancer Network Oncology Research Program Funded Through GlaxoSmithKline
9/6/2012
-
Researchers Receive Grants From National Comprehensive Cancer Network Oncology Research Program Funded Through Boehringer Ingelheim Corporation
9/4/2012
-
Highlights of the National Comprehensive Cancer Network 17th Annual Conference Include Presentations on Lung Cancer Screening, Melanoma, and Non-Hodgkin’s Lymphomas
3/29/2012
-
National Comprehensive Cancer Network Presents New Guidelines for Acute Lymphoblastic Leukemia
3/21/2012
-
National Comprehensive Cancer Network to Hold 17th Annual Conference: Sam Donaldson and Clifford Goodman Lead Roundtable Discussions on Critical Issues in Cancer Care
3/13/2012
-
National Comprehensive Cancer Network Collaborates with AVEO Pharmaceuticals, Inc. and Astellas Pharma Inc. on Innovative Cancer Research
2/17/2012
-
National Comprehensive Cancer Network Receives $2 Million in Oncology Research Funding from Boehringer Ingelheim Corporation to Investigate Afatinib in Solid Tumors
11/10/2011
-
National Comprehensive Cancer Network Guidelines Emphasize Patient Preference as Key to Selection of Maintenance Therapy in Follicular Lymphoma
9/15/2011
-
National Comprehensive Cancer Network Expert Discusses Extending Life-Saving Pediatric Treatments to Adults with Acute Lymphoblastic Leukemia
9/14/2011
-
Threshold Pharmaceuticals, Inc. Announces National Comprehensive Cancer Network Grant for Phase 1 Trial of TH-302 in Combination with Pazopanib
7/6/2011
-
Threshold Pharmaceuticals, Inc. Announces National Comprehensive Cancer Network Grant for Phase 1 Trial of TH-302 in Combination with Pazopanib
7/6/2011
-
National Comprehensive Cancer Network Guidelines Available in Elekta's MOSAIQ EMR
6/8/2011
-
National Comprehensive Cancer Network Receives $4 Million in Oncology Research Funding from GlaxoSmithKline
7/27/2010